A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
Status:
Completed
Trial end date:
2021-02-15
Target enrollment:
Participant gender:
Summary
Disease and Stage: naïve metastatic kidney cancer.
A multicenter, randomized, a Phase 2 BIOmarker driven trial with Nivolumab and Ipilimumab or
VEGFR tKi in naïve metastatic Kidney cancer
Phase:
Phase 2
Details
Lead Sponsor:
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie